These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 33111350)
21. Safety and Efficacy of Intravenous Ferric Carboxy Maltose in Iron Deficiency Anaemia During Post-partum Period. Mishra V; Roy P; Gandhi K; Choudhary S; Aggarwal R; Sokabaj S J Nepal Health Res Counc; 2018 Jan; 15(3):208-211. PubMed ID: 29353890 [TBL] [Abstract][Full Text] [Related]
22. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S Digestion; 2012; 85(1):47-54. PubMed ID: 22179489 [TBL] [Abstract][Full Text] [Related]
23. Ferric carboxymaltose (Injectafer) for iron deficiency anemia. Med Lett Drugs Ther; 2013 Dec; 55(1431):99-100. PubMed ID: 24322665 [No Abstract] [Full Text] [Related]
24. Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose: A Case Report. Brunetta DM; Kaufman J; De Santis GC; Mesquita DF; Souza FN; Garcia JH Transplant Proc; 2015 Oct; 47(8):2548-51. PubMed ID: 26518969 [TBL] [Abstract][Full Text] [Related]
25. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Pollock RF; Muduma G Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520 [TBL] [Abstract][Full Text] [Related]
26. Ferric carboxymaltose approved for iron deficiency anemia. Thompson CA Am J Health Syst Pharm; 2013 Sep; 70(17):1458. PubMed ID: 23943169 [No Abstract] [Full Text] [Related]
27. Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. Lofruthe N; Gallitz I; Traeger L; Bäumer N; Schulze I; Kuhlmann T; Müller-Tidow C; Steinbicker AU PLoS One; 2016; 11(7):e0158599. PubMed ID: 27404499 [TBL] [Abstract][Full Text] [Related]
28. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
29. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
30. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Pollock RF; Muduma G Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458 [TBL] [Abstract][Full Text] [Related]
31. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Keeler BD; Simpson JA; Ng S; Tselepis C; Iqbal T; Brookes MJ; Acheson AG Colorectal Dis; 2014 Oct; 16(10):794-800. PubMed ID: 24916374 [TBL] [Abstract][Full Text] [Related]
32. Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department. Motta I; Mantovan G; Consonni D; Brambilla AM; Materia M; Porzio M; Migone De Amicis M; Montano N; Cappellini MD Intern Emerg Med; 2020 Jun; 15(4):629-634. PubMed ID: 31707563 [TBL] [Abstract][Full Text] [Related]
33. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Keeler BD; Simpson JA; Ng O; Padmanabhan H; Brookes MJ; Acheson AG; Br J Surg; 2017 Feb; 104(3):214-221. PubMed ID: 28092401 [TBL] [Abstract][Full Text] [Related]
34. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
35. [Iron deficiency therapy: focus is on the patient]. Girrbach G MMW Fortschr Med; 2016 May; 158(10):88. PubMed ID: 27221451 [No Abstract] [Full Text] [Related]
36. Iron in heart failure: friend or foe? Jelani QU; Katz SD Curr Heart Fail Rep; 2010 Jun; 7(2):49-51. PubMed ID: 20424991 [No Abstract] [Full Text] [Related]